CARB-X

Today is World Phage Day – a day to recognize the potential of bacteriophages to address drug-resistant bacteria. Bold innovation is necessary to tackle antimicrobial resistance (AMR), and bacteriophages have the potential to offer targeted alternatives or complement traditional antibiotics. CARB-X supports multiple projects that are exploring phage-based solutions to AMR. Locus Biosciences, Inc.'s CRISPR CAS-3 bacteriophage cocktail aims to treat serious recurring urinary tract infections caused by K. pneumoniae. This project has been in the CARB-X portfolio since July 2020 and is in the pre-clinical stage: bit.ly/48zZbYO SNIPR Biome - A CRISPR Company is pioneering a novel use of CRISPR/Cas technology to selectively eradicate target bacteria based on specific DNA sequence signatures in the bacterial genome, while leaving the rest of the patient’s microbiome intact. This precision therapy would target E. Coli bacteria in cancer patients with hematological malignancies. SNIPR Biome’s project has been in the CARB-X portfolio since March 2021 and is now in a Phase 1b clinical trial: bit.ly/4hamzy4 PHIOGEN's next-generation phage-based project aims to reduce mortality and recurrence in patients suffering from life-threatening bacterial sepsis by combining immediate bacterial killing with long-term immune protection from subsequent infections: bit.ly/41eNClc #WorldPhageDay #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology  

Join CARB-X Chief Scientific Officer Richard Alm, PhD, at the La Trobe University Frontiers in Infectious Diseases Innovation event for his presentation “CARB-X – Accelerating the Development of Novel Products to Tackle AMR.” Dr. Alm will discuss the evolution of CARB-X and how it accelerates a diverse portfolio of novel antibacterial products toward clinical development and regulatory approval through non-dilutive funding, expert technical support, and Portfolio Acceleration Tools. 📆 Wednesday, October 29 ⏰ 5 – 7 PM AEDT 🔗 Register here: bit.ly/3IOo9Jy #AMR #AntibioticResistance #StopSuperBugs #GlobalHealth #Medicine #DrugDevelopment #AntibioticDevelopment

Congratulations to CARB-X product developer Lumen Bioscience on its recent successful Series C financing and the addition of Jeff Raikes as an independent board director.    CARB-X is proud to have supported LMN-0403, an orally delivered preventative and treatment of diarrheal diseases caused by Campylobacter jejuni and enterotoxigenic Escherichia coli, since August 2020. This antibiotic-alternative biologic cocktail has been developed with Lumen’s proprietary manufacturing technology that utilizes recombinant expression in spirulina to produce therapeutic biologic products.    #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology   

A recent publication in Nature Portfolio Communications Medicine, co-authored by Erin Duffy, PhD, proposes a comprehensive One Health stewardship framework to address antimicrobial resistance (AMR). The authors emphasize that AMR is a complex, interconnected issue that requires stewardship throughout the entire antimicrobial lifecycle. The framework centers on four stewardship pillars: prevention, innovation, access, and care. Within the framework’s innovation pillar, CARB-X and Global Antibiotic R&D Partnership (GARDP) are recognized as important push incentives supporting antibiotic research and development. 🔗 Read the publication here: bit.ly/3KSyMvh #OneHealth #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology  

Join us to learn about ReadyDetect, a $10M prize competition from BARDA and ULP aimed at accelerating the development of next-generation antigen-based diagnostics. Discover how your innovation could stand out as a winner and take a major step toward advancing impactful, accessible diagnostic solutions. 📅 Thursday, October 30, 2025 🕙10:00 AM – 11:00 AM PT Hear from Seila S., PhD (BARDA) and Stephanie Chan, PhD (ULP) about eligibility, program structure, and how to get involved. Plus a live Q&A to answer your questions. 👉 Register now: https://hubs.ly/Q03N_xv20

Exciting news: University Lab Partners and BARDA have launched ReadyDetect, a $10M competition to accelerate the development of next-generation diagnostics. This global challenge seeks innovative, low-cost, and highly accurate antigen tests that can be deployed outside of traditional labs to strengthen public health response. 👉 Learn more about the competition and how to apply: https://lnkd.in/gqxwEaqt

Join CARB-X Chief of External Affairs Damiano de Felice at the World Economic Forum Annual Meeting of the Global Future Councils panel “What Is the Cost of Underinvesting in Health?” The panel will discuss the societal and economic consequences of underinvesting in health and what solutions can be implemented to address them, including the important role of international collaboration in closing global health gaps. The panel will also explore innovative financing models for sustainable health investment. 📆 Wednesday, October 15 ⏰ 12:15 – 1 PM GST 🔗 Watch the livestream here: bit.ly/3LaW1AP #AMGFCC25 #AMR #AntibioticResistance #StopSuperBugs #GlobalHealth #Medicine #DrugDevelopment #AntibioticDevelopment

Join CARB-X Alliance Director Ed T. Buurman, PhD, MBA at The World Vaccine Congress Europe keynote panel “Vaccines & AMR – Turning Commitment into Practical Action.” The panel will explore how AMR political commitments can be channeled into tangible support for early vaccine research and development, discuss which pathogens and settings should shape the next wave of AMR vaccine innovation, and discuss how to support fragile AMR vaccine pipelines. The panel will also talk about strengthening the early evidence base that vaccines reduce antibiotic use to address data gaps that still limit confidence in investment. 📆 Tuesday, October 14 ⏰ 5 PM CEST 🔗 Register now: bit.ly/3IdV8Xm #WVCEU #AMR #AntibioticResistance #StopSuperBugs #GlobalHealth #Medicine #DrugDevelopment #AntibioticDevelopment #VaccineDevelopment

Join CARB-X Executive Director Kevin Outterson at the World Health Summit panel “Leveraging Evidence and Tools to Advance AMR Policy Implementation.” This session will discuss the intersection of data, interventions, and policy in developing solutions for antimicrobial resistance and explore how countries and stakeholders can better harness existing data and tools to implement impactful and accountable AMR policies. 📆 Sunday, October 12 ⏰ 11 – 12:30 CEST 🔗 Register now: bit.ly/4maIw0R #WHS2025 #AMR #AntibioticResistance #StopSuperBugs #GlobalHealth #Medicine #DrugDevelopment #AntibioticDevelopment   

Thank you to CARB-X product developers, funders, and external speakers who convened at Imperial College London on September 30 for the annual CARB-X PD Conference! We welcomed more than 130 participants who came together to share and explore innovations to address antibiotic resistance. Attendees heard from a variety of presenters, including clinicians, CARB-X portfolio graduates, and CARB-X R&D Leaders across the therapeutics, preventatives, and diagnostics pillars. CARB-X extends its deepest gratitude to everyone who came together in London to participate in these important discussions on innovation to protect lives from bacterial infections. We enjoyed the opportunity to connect with everyone in person! #AMR #StopSuperBugs #SuperBugs #AntibioticResistance #Medicine #GlobalHealth #ProductDevelopment #Innovation #Biotechnology  Boston University School of Law Boston University Biomedical Advanced Research and Development Authority (BARDA) National Institute of Allergy and Infectious Diseases (NIAID) Wellcome Trust Bundesministerium für Forschung, Technologie und Raumfahrt Gates Foundation Government of Canada Novo Nordisk Foundation Ministero dell'economia e delle finanze Centre for Cellular and Molecular Platforms (C-CAMP) German Center for Infection Research Institute For Life Science Entrepreneurship (ILSE) Photos by Kalory | Photo & Video |